



Clinical trial results:

A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients

Summary

EudraCT number	2009-012259-21
Trial protocol	ES GB DE BE FR
Global end of trial date	21 March 2017

Results information

Result version number	v1
This version publication date	28 March 2018
First version publication date	28 March 2018

Trial information

Trial identification

Sponsor protocol code	F506-CL-0404
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01371344
WHO universal trial number (UTN)	-
Other trial identifiers	Acronym: PROGRESSION

Notes:

Sponsors

Sponsor organisation name	Astellas Pharma Europe, Ltd
Sponsor organisation address	2000 Hillswood Drive, Chertsey, United Kingdom, KT16 0RS
Public contact	Clinical Trial Disclosure, Astellas Pharma Europe, Ltd, Astellas.resultsdisclosure@astellas.com
Scientific contact	Clinical Trial Disclosure, Astellas Pharma Europe, Ltd, Astellas.resultsdisclosure@astellas.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	06 May 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 March 2017
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The study had 2 parts: Part A (F506-CL-0404A) and Part B (F506-CL-0404B). The objective of F506-CL-0404A was to monitor the safety of and efficacy of Modigraf® (tacrolimus granules) in stable paediatric allograft recipients.

The objective of F506-CL-0404B was to monitor dose changes and tacrolimus whole blood trough levels after conversion from a tacrolimus granules based immunosuppression regimen to a Prograf® (tacrolimus capsules) based immunosuppression regimen.

Protection of trial subjects:

This clinical study was written, conducted and reported in accordance with the protocol, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines, and applicable local regulations, including the European Directive 2001/20/EC, on the protection of human rights, and with the ethical principles that have their origin in the Declaration of Helsinki. Astellas ensures that the use and disclosure of protected health information (PHI) obtained during a research study complies with the federal, national and/or regional legislation related to the privacy and protection of personal information.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 June 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	Spain: 26
Country: Number of subjects enrolled	United Kingdom: 9
Worldwide total number of subjects	47
EEA total number of subjects	47

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	17
Children (2-11 years)	29
Adolescents (12-17 years)	1
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Children aged ≤ 12 years were enrolled at 11 sites in a total of 6 countries: UK (2 sites), Spain (3 sites), Germany (2 sites), Belgium (1 site), Poland (1 site) and France (2 sites).

Pre-assignment

Screening details:

Pediatric participants who had undergone liver, kidney or heart transplantation and who had previously participated F506-CL-0403 study were enrolled in Part A of this study. Participants who participated in Part A and who were converted to receive tacrolimus capsules were enrolled in Part B. Results reported here include data from Part A.

Period 1

Period 1 title	Part A (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part A: Heart Transplant

Arm description:

Participants who were heart transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.

Arm type	Experimental
Investigational medicinal product name	Tacrolimus granules
Investigational medicinal product code	FK506
Other name	Modigraf®
Pharmaceutical forms	Granules for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Participants received the same dose regimen as they were receiving at the end of the F506-CL-0403 study, and the first dose was administered on day 1. Subsequent oral tacrolimus doses were adjusted by the investigator based on clinical evidence of efficacy and occurrence of AEs and observing the recommended whole blood trough level range of 5 to 20 ng/ml. The tacrolimus granules for oral suspension were available in sachets containing either 0.2 mg or 1 mg tacrolimus granules per sachet.

Arm title	Part A: Liver Transplant
------------------	--------------------------

Arm description:

Participants who were liver transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.

Arm type	Experimental
Investigational medicinal product name	Tacrolimus granules
Investigational medicinal product code	FK506
Other name	Modigraf®
Pharmaceutical forms	Granules for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Participants received the same dose regimen as they were receiving at the end of the F506-CL-0403 study, and the first dose was administered on day 1. Subsequent oral tacrolimus doses were adjusted by the investigator based on clinical evidence of efficacy and occurrence of AEs and observing the recommended whole blood trough level range of 5 to 20 ng/ml. The tacrolimus granules for oral suspension were available in sachets containing either 0.2 mg or 1 mg tacrolimus granules per sachet.

Arm title	Part A: Kidney Transplant
Arm description: Participants who were kidney transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.	
Arm type	Experimental
Investigational medicinal product name	Tacrolimus granules
Investigational medicinal product code	FK506
Other name	Modigraf®
Pharmaceutical forms	Granules for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Participants received the same dose regimen as they were receiving at the end of the F506-CL-0403 study, and the first dose was administered on day 1. Subsequent oral tacrolimus doses were adjusted by the investigator based on clinical evidence of efficacy and occurrence of AEs and observing the recommended whole blood trough level range of 5 to 20 ng/ml. The tacrolimus granules for oral suspension were available in sachets containing either 0.2 mg or 1 mg tacrolimus granules per sachet.

Number of subjects in period 1	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant
Started	17	18	12
Completed	16	11	10
Not completed	1	7	2
Intolerable Adverse Event	-	1	1
Withdrawal of Consent	-	3	1
Other	-	1	-
Lost to follow-up	1	-	-
Retransplantation	-	2	-

Baseline characteristics

Reporting groups

Reporting group title	Part A: Heart Transplant
-----------------------	--------------------------

Reporting group description:

Participants who were heart transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.

Reporting group title	Part A: Liver Transplant
-----------------------	--------------------------

Reporting group description:

Participants who were liver transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.

Reporting group title	Part A: Kidney Transplant
-----------------------	---------------------------

Reporting group description:

Participants who were kidney transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.

Reporting group values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant
Number of subjects	17	18	12
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	5.3 ± 4.1	2.3 ± 2.8	5.4 ± 3.0
Gender categorical Units:			
Male	13	10	9
Female	4	8	3
Race Units: Subjects			
White	17	18	11
Black or African American	0	0	0
Asian	0	0	1
Other	0	0	0

Reporting group values	Total		
Number of subjects	47		
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	-		
---	---	--	--

Gender categorical Units:			
Male	32		
Female	15		
Race Units: Subjects			
White	46		
Black or African American	0		
Asian	1		
Other	0		

End points

End points reporting groups

Reporting group title	Part A: Heart Transplant
Reporting group description: Participants who were heart transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.	
Reporting group title	Part A: Liver Transplant
Reporting group description: Participants who were liver transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.	
Reporting group title	Part A: Kidney Transplant
Reporting group description: Participants who were kidney transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.	

Primary: Part A: Number of Participants with Acute Rejection Episodes

End point title	Part A: Number of Participants with Acute Rejection Episodes ^[1]
End point description: Rejection episodes/acute rejections were indicated by clinical and/or laboratory signs, and were classified according to their rejection specific treatment: •Spontaneously Resolving Acute Rejection: not treated with new or increased corticosteroid medication, antibodies or any other medication and resolved, irrespective of any tacrolimus dose changes; •Corticosteroid Sensitive Acute Rejection: treated with new or increased corticosteroid medication only and which has resolved, irrespective of any tacrolimus dose changes; •Corticosteroid Resistant Acute Rejection: did not resolve following treatment with corticosteroids; - Resolved with further treatment: any acute rejection with an end date AND a treatment other than corticosteroid used; - Unresolved with further treatment: any acute rejection with no end date AND a treatment other than corticosteroid used; - Unresolved with no further treatment: any acute rejection with no end date AND ONLY corticosteroid treatment was used. SAF.	
End point type	Primary
End point timeframe: Up to 12 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this is a single-arm study, there were no pre-determined hypothetical or comparative statistical analyses performed in Part A of the study.

End point values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	18	12	
Units: Participants				
Spontaneously Resolving Acute Rejection	1	0	0	
Corticosteroid Sensitive Acute Rejection	3	2	0	
Corticosteroid Resistant Acute Rejections	0	1	0	
Other Acute Rejections	1	0	1	

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Severity of BPARs

End point title	Part A: Severity of BPARs ^[2]
-----------------	--

End point description:

The severity of BPARs was categorized with specific criteria by organ: For kidney transplant participants, according to Banff '97 Diagnostic categories for renal allograft biopsies – Banff '07 update (C4d deposition, Acute antibody-mediated rejection I, II, and III, Acute T cell mediated rejection IA, IB, IIA, IIB and III); for liver transplant participants, according to 1997 Banff Schema for Grading of Liver Allograft Rejection - Rejection Activity Index score (sum of grades: 1-mild, 2-moderate, 3-severe; range from 0-9); for heart, according to Standardized Nomenclature of the International Society of Heart and Lung Transplantation - Standardised Cardiac Biopsy Grading: Acute Cellular Rejection 2004 (mild, moderate, severe). The analysis population was the Safety Analysis Set (SAF), which consisted of participants took at least 1 dose of study drug. Categories not applicable to the reporting groups are denoted as "99999."

End point type	Primary
----------------	---------

End point timeframe:

Up to 12 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this is a single-arm study, there were no pre-determined hypothetical or comparative statistical analyses performed in Part A of the study.

End point values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	18	12	
Units: Participants				
Heart: Mild	2	99999	99999	
Heart: Moderate	0	99999	99999	
Heart: Severe	0	99999	99999	
Liver RAI Score 0-2	99999	0	99999	
Liver RAI Score 3	99999	0	99999	
Liver RAI Score 4-5	99999	0	99999	
Liver RAI Score 6-7	99999	2	99999	
Liver RAI Score 8-9	99999	1	99999	
Kidney: C4d deposition	99999	99999	0	
Kidney: Acute antibody-mediated rejection I	99999	99999	0	
Kidney: Acute antibody-mediated rejection II	99999	99999	0	
Kidney: Acute antibody-mediated rejection III	99999	99999	0	
Kidney: T-cell mediated rejection IA	99999	99999	0	
Kidney: T-cell mediated rejection IB	99999	99999	0	
Kidney: T-cell mediated rejection IIA	99999	99999	0	
Kidney: T-cell mediated rejection IIB	99999	99999	0	

Kidney: T-cell mediated rejection III	99999	99999	0	
---------------------------------------	-------	-------	---	--

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Patient Survival

End point title	Part A: Patient Survival ^[3]
-----------------	---

End point description:

Patient survival was reported as the number of deaths that occurred during Part A of the study. The analysis population was the SAF.

End point type	Primary
----------------	---------

End point timeframe:

Up to 12 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this is a single-arm study, there were no pre-determined hypothetical or comparative statistical analyses performed in Part A of the study.

End point values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	18	12	
Units: Participants				
Deaths	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Graft Survival

End point title	Part A: Graft Survival ^[4]
-----------------	---------------------------------------

End point description:

Graft survival was reported as the number of participants who experienced graft loss. Graft loss was defined as retransplantation or death or return to pretransplantation treatment modality for 6 weeks or longer. Additionally, kidney transplanted patients with ongoing dialysis at the end of study were counted as patients with graft loss. The analysis population was the SAF.

End point type	Primary
----------------	---------

End point timeframe:

Up to 12 months

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this is a single-arm study, there were no pre-determined hypothetical or comparative statistical analyses performed in Part A of the study.

End point values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	18	12	
Units: Participants				
Graft losses	0	2	0	

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Participants with Adverse Events (AEs)

End point title	Part A: Number of Participants with Adverse Events (AEs) ^[5]
-----------------	---

End point description:

Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. clinical laboratory tests, vital signs, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A serious AE (SAE) was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important. A treatment emergent adverse event (TEAE) was defined as an AE observed after investigational drug administration. The analysis population was the SAF.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug up to 30 days after last dose of study drug (up to 13 months)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this is a single-arm study, there were no pre-determined hypothetical or comparative statistical analyses performed in Part A of the study.

End point values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	18	12	
Units: Participants				
Any TEAE	16	15	12	
Drug-related TEAEs	9	12	11	
Deaths	0	0	0	
Serious TEAEs	8	9	9	
Drug-related Serious TEAEs	3	2	7	
Deaths Resulting from AEs	0	0	0	
TEAEs Leading to Discontinuation of Study Drug	0	1	2	
Drug-related TEAEs Leading to Disc. of Study Drug	0	1	2	

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Tacrolimus Mean Trough Levels

End point title | Part A: Tacrolimus Mean Trough Levels^[6]

End point description:

The analysis population was the SAF. N indicates the number of participants with available data. Due to participants discontinuing the study drug at certain time points, data were not calculated and denoted as "99999."

End point type | Primary

End point timeframe:

Day 1, Months 1, 2, 3, 6, 9, 12 (prior to each study drug dosing)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this is a single-arm study, there were no pre-determined hypothetical or comparative statistical analyses performed in Part A of the study.

End point values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	18	12	
Units: ng/mL				
arithmetic mean (standard deviation)				
Day 1 [N=8, 15, 9]	8.76 (± 2.38)	11.68 (± 4.60)	11.71 (± 3.64)	
Month 1 [N=17, 18, 11]	11.74 (± 5.07)	9.80 (± 3.34)	7.11 (± 2.41)	
Month 2 [N=16, 12, 11]	9.80 (± 4.01)	9.15 (± 2.28)	5.65 (± 1.58)	
Month 3 [N=15, 11, 11]	9.29 (± 3.17)	12.82 (± 11.97)	6.50 (± 1.97)	
Month 6 [N=1, 1, 7]	5.30 (± 99999)	19.20 (± 99999)	7.37 (± 5.09)	
Month 9 [N=1, 0, 6]	3.40 (± 99999)	99999 (± 99999)	5.12 (± 0.99)	
Month 12 [N=0, 0, 6]	99999 (± 99999)	99999 (± 99999)	4.95 (± 0.65)	
Last Day on Study Drug [17, 18, 11]	8.30 (± 2.13)	11.73 (± 9.77)	5.13 (± 1.71)	

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Number of Dose Adjustments

End point title | Part A: Number of Dose Adjustments^[7]

End point description:

Study drug doses were to be adjusted based on clinical evidence of efficacy and occurrence of adverse events, and taking into consideration the recommended whole blood trough level range of 5-20 ng/ml. The analysis population was the SAF. N indicates the number of participants with available data. Due to participants discontinuing the study drug at certain time points, data were not calculated and are denoted as "99999."

End point type | Primary

End point timeframe:

Months 1, 2, 3, 6, 9, 12

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As this is a single-arm study, there were no pre-determined hypothetical or comparative statistical analyses performed in Part A of the study.

End point values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	18	10	
Units: dose adjustments				
arithmetic mean (standard deviation)				
Month 1 [N=17, 18, 8]	7.6 (± 5.3)	12.1 (± 8.5)	4.3 (± 3.3)	
Month 2 [N=10, 9, 5]	2.2 (± 1.4)	5.8 (± 4.3)	3.8 (± 5.7)	
Month 3 [N=1, 5, 6]	2.0 (± 99999)	3.2 (± 1.9)	1.2 (± 0.4)	
Month 6 [N=1, 0, 4]	2.0 (± 99999)	99999 (± 99999)	1.8 (± 1.0)	
Month 9 [N=0, 0, 2]	99999 (± 99999)	99999 (± 99999)	2.0 (± 0.0)	
Month 12 [N=0, 0, 1]	99999 (± 99999)	99999 (± 99999)	1.0 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Number of Participants with Biopsy-proven Acute Rejection Episodes (BPARs)

End point title	Part A: Number of Participants with Biopsy-proven Acute Rejection Episodes (BPARs)
-----------------	--

End point description:

BPAR episodes were defined as acute rejection episodes confirmed by biopsy, and were classified according to their rejection specific treatment: •Spontaneously Resolving Acute Rejection: not treated with new or increased corticosteroid medication, antibodies or any other medication and resolved, irrespective of any tacrolimus dose changes; •Corticosteroid Sensitive Acute Rejection: treated with new or increased corticosteroid medication only and which has resolved, irrespective of any tacrolimus dose changes; •Corticosteroid Resistant Acute Rejection: did not resolve following treatment with corticosteroids; - Resolved with further treatment: any acute rejection with an end date AND a treatment other than corticosteroid used; - Unresolved with further treatment: any acute rejection with no end date AND a treatment other than corticosteroid used; - Unresolved with no further treatment: any acute rejection with no end date AND ONLY corticosteroid treatment used. SAF.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 12 months

End point values	Part A: Heart Transplant	Part A: Liver Transplant	Part A: Kidney Transplant	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	18	12	
Units: participants				
number (not applicable)				
Spontaneously Resolving Acute Rejection	0	0	0	
Corticosteroid Sensitive Acute Rejection	2	2	0	
Corticosteroid Resistant Acute Rejection	0	1	0	
Other Acute Rejections	0	0	0	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to 30 days after last dose of study drug (up to 13 months)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.0
--------------------	------

Reporting groups

Reporting group title	Part A: Heart Transplant
-----------------------	--------------------------

Reporting group description:

Participants who were heart transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.

Reporting group title	Part A: Kidney Transplant
-----------------------	---------------------------

Reporting group description:

Participants who were kidney recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.

Reporting group title	Part A: Liver Transplant
-----------------------	--------------------------

Reporting group description:

Participants who were liver transplant recipients received tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country in Part A of the study.

Serious adverse events	Part A: Heart Transplant	Part A: Kidney Transplant	Part A: Liver Transplant
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 17 (47.06%)	9 / 12 (75.00%)	9 / 18 (50.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Surgical and medical procedures			
Central venous catheter removal			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Drug interaction			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Treatment noncompliance			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Lung consolidation			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	2 / 18 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Body temperature increased			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hepatic enzyme increased subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Biliary anastomosis complication subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complications of transplanted liver subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal anastomotic leak subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac hypertrophy subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Tachycardia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurotoxicity			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	2 / 17 (11.76%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic vein thrombosis			

subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver disorder			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Oliguria			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacterial sepsis			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	2 / 17 (11.76%)	1 / 12 (8.33%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			
subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			

subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal protozoal infection			
subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 17 (0.00%)	2 / 12 (16.67%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 17 (0.00%)	2 / 12 (16.67%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	9 / 10	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Acidosis			

subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Part A: Heart Transplant	Part A: Kidney Transplant	Part A: Liver Transplant
Total subjects affected by non-serious adverse events			
subjects affected / exposed	16 / 17 (94.12%)	11 / 12 (91.67%)	15 / 18 (83.33%)
Vascular disorders			
Diastolic hypertension			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	5 / 17 (29.41%)	2 / 12 (16.67%)	3 / 18 (16.67%)
occurrences (all)	5	2	3
Hypotension			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Thrombosis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Surgical and medical procedures			
Catheter removal			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Central venous catheter removal			

subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
General disorders and administration site conditions			
Chills			
subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Device occlusion			
subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	2 / 12 (16.67%) 2	0 / 18 (0.00%) 0
Generalised oedema			
subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Pyrexia			
subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	1 / 12 (8.33%) 4	3 / 18 (16.67%) 4
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Hypogammaglobulinaemia			
subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Seasonal allergy			
subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	2 / 12 (16.67%) 2	0 / 18 (0.00%) 0
Reproductive system and breast disorders			
Genital pain			
subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	7 / 12 (58.33%) 8	1 / 18 (5.56%) 1
Oropharyngeal pain			

subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Pleural effusion subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Pneumothorax subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Pulmonary haemorrhage subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Rhinorrhoea subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	4 / 12 (33.33%) 5	0 / 18 (0.00%) 0
Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Wheezing subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Psychiatric disorders Sleep disorder subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Vomiting psychogenic subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Blood creatinine increased			

subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	2 / 12 (16.67%) 2	0 / 18 (0.00%) 0
Blood magnesium decreased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Blood pressure increased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Body temperature increased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Immunosuppressant drug level increased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Injury, poisoning and procedural complications			
Complications of transplanted kidney subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Complications of transplanted liver subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	2 / 18 (11.11%) 2
Contusion subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Radius fracture			

subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Cardiac disorders			
Hypertrophic cardiomyopathy subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Pericardial effusion subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	0 / 18 (0.00%) 0
Ventricular tachycardia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	0 / 18 (0.00%) 0
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 2	0 / 18 (0.00%) 0
Hypertonia subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Tremor subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	2 / 12 (16.67%) 2	4 / 18 (22.22%) 5
Haemolytic anaemia subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	4 / 17 (23.53%) 4	1 / 12 (8.33%) 1	3 / 18 (16.67%) 5
Ear and labyrinth disorders			

Ear pain subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Eye disorders Conjunctivitis subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Eye swelling subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	4 / 17 (23.53%) 4	7 / 12 (58.33%) 13	3 / 18 (16.67%) 5
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	0 / 18 (0.00%) 0
Mouth ulceration subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Vomiting subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	6 / 12 (50.00%) 13	8 / 18 (44.44%) 10
Hepatobiliary disorders Bile duct obstruction subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Bile duct stenosis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Hepatotoxicity			

subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Portal vein thrombosis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	0 / 18 (0.00%) 0
Dermatitis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Dermatitis exfoliative subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Drug eruption subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Eczema subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Rash subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Swelling face subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Renal and urinary disorders			
Dysuria			

subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Nephropathy toxic subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Renal failure subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	0 / 18 (0.00%) 0
Renal impairment subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	3 / 18 (16.67%) 3
Renal injury subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	0 / 18 (0.00%) 0
Urinary retention subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 12 (8.33%) 1	0 / 18 (0.00%) 0
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	2 / 18 (11.11%) 2
Infections and infestations Abdominal infection subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Biliary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Biliary tract infection fungal subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 12 (0.00%) 0	1 / 18 (5.56%) 1
Clostridial infection subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 12 (0.00%) 0	0 / 18 (0.00%) 0
Device related infection			

subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Epstein-Barr virus infection			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	3 / 18 (16.67%)
occurrences (all)	0	0	3
Gastroenteritis norovirus			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Gastrointestinal candidiasis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Genital infection male			
subjects affected / exposed	1 / 17 (5.88%)	0 / 12 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Herpes zoster			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Human herpesvirus 6 infection			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	6 / 18 (33.33%)
occurrences (all)	0	0	6
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	0 / 17 (0.00%)	4 / 12 (33.33%)	1 / 18 (5.56%)
occurrences (all)	0	4	1
Oral candidiasis			
subjects affected / exposed	0 / 17 (0.00%)	2 / 12 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Oral fungal infection			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Peritonitis bacterial			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

Pneumonia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 17 (5.88%)	2 / 12 (16.67%)	0 / 18 (0.00%)
occurrences (all)	2	2	0
Viral infection			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hyperkalaemia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hyperphosphataemia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 12 (8.33%)	2 / 18 (11.11%)
occurrences (all)	0	1	3
Hypomagnesaemia			
subjects affected / exposed	4 / 17 (23.53%)	1 / 12 (8.33%)	6 / 18 (33.33%)
occurrences (all)	4	1	6
Hyponatraemia			
subjects affected / exposed	0 / 17 (0.00%)	2 / 12 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Hypophosphataemia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Metabolic acidosis			

subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	7 / 18 (38.89%)
occurrences (all)	0	0	8
Vitamin D deficiency			
subjects affected / exposed	0 / 17 (0.00%)	0 / 12 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This study has been terminated during Part B, due to low number of participants enrolled in Part B. When results are available for Part B, these results will be updated to include these in this disclosure.

Notes: